IthaMaps

Welcome to IthaMaps

IthaMaps is a global epidemiology database of heamoglobinopathies, illustrating published data on a dynamic global to regional map. Country-specific information on haemoglobinopathy-related policies, prevalence, incidence and overall disease burden is given, including relative allele frequencies of specific globin mutations in each country and/or region, dynamically linked to corresponding IthaGenes entries.

IthaMaps content was supported by partnership with the HVP Global Globin 2020 Challenge

Search

Search Country:		OR	Search for:		Show organisations

Healthcare information:
Major haemoglobinopathies:

Mutation search

Select locus:		Select mutation:

More Fewer search options

General information for Philippines

Philippines

Continent:	Asia
Capital:	Manila
Population:	99900177
Area (in sq km):	300000.0

Haemoglobinopathy-specific healthcare policy information for Philippines

Healthcare policy		Comment/Info	Reference
Prevention programme:	No	From: Thalassaemia Reports 2012, TIF Pan-Asian Conference.
SCD newborn screening:	Yes (National)	Haemoglobinopathy NBS since 2014, performed by 7400+ hospitals and birthing centers.	[PMID: 34204320]
Prenatal screening:	No
Rare disease patient registry:	No	Largely institution-specific databases.	[PMID: 27484654]
Dedicated treatment centres:	Yes (National)	Newborn screening continuity clinics (NBSCC) providing medical follow-up and referral to regional disease specialists.	[PMID: 34204320]
Blood transfusion availability:	No	Limited to a few centres, such as The Philippine Childrens Medical Centre. From: Thalassaemia Reports 2012, TIF Pan-Asian Conference.
Iron chelation availability:	Yes (National)	Iron chelators (DFO, DFP, DFX) and combination DFO and DFP are available, but purchased by personal funds. From: Thalassaemia Reports 2012, TIF Pan-Asian Conference.
MRI facilities:	No	From: TIF report on South East Asian Nations, Aug. 2013.
Patient associations:	Yes (National)	E.g. Balikatang Thalassemia (Ba-Tha) was founded in 1993.
Genetic counselling:	Yes (National)	Newborn screening continuity clinics (NBSCC) oversight and consultation is provided by three Centers for Human Genetic Services (CHGS). Each of the NBSCCs is directed by a medical geneticist knowledgeable in linking primary care physicians to regional disease specialist.	[PMID: 34204320]

Prevalence and incidence of major haemoglobinopathies in Philippines

Haemoglobinopathy		Reference
Prevalence of β-thalassaemia carriers:	1.2 % of the population	[PMID: 27040959]
Prevalence of α-thalassaemia carriers:	5 % of the population
Prevalence of Hb E carriers:	0.4 % of the population	[PMID: 27040959]
Expected incidence of β-thalassaemia:	153 expected affected births/year	[PMID: 24672827]
Known β-thalassaemia patients:	600 patients	[PMID: 24672827]

Global Burden of Disease data for Philippines

Migration data for Philippines

Mutation frequencies in Philippines

No mutation frequencies are currently available for Philippines

Organisations in Philippines

Organisations in Philippines are currently not available

Microattributions

No microattibutions were provided for Philippines. Please contact us, if you are willing to review existing information or provide new data.

To provide new epidemiological information and/or report mistakes, please register/log in first or use the Contact Us form.

Important Note: The relative allele frequencies presented in IthaMaps are not calculated by ITHANET, but they are extracted from the corresponding publications. ITHANET is not responsible for any mistakes in the data. Please use this information with caution! We encourage scientists that have more detailed or updated epidemiological information to contact us.

Disclaimer: The information on this website is provided as an information resource only and must not to be used as a substitute for professional diagnosis and treatment. The ITHANET Portal and IthaMaps are not responsible or liable for any advice, course of treatment, diagnosis or any other information, services or products that an individual obtains through this website.

Note: The information you provide for the specific country will appear on the IthaMaps website and your contribution will be acknowledged.

Country:

Contributor's details

To be included in ITHANET Organisations & Experts

Name:		Organisation's name:
Surname:		Organisation's brief description:
Title:		Organisation's address:
Expertise/Research interests:		Organisation's City:
Address:		Organisation's Country:
City:		Organisation's website:
Country:		E-mail:
ORCID

Healthcare Policies

Health-policy	Select one Answer	Comment
Prevention programme
SCD newborn screening
Prenatal screening
Antenatal screening
Haemoglobinopathies patient registry
Rare disease patient registry
Dedicated treatment centres
Blood transfusion availability
Iron chelation availability
MRI facilities
Patient associations
Genetic counselling

Status of major Haemoglobinopathies

In Expected Incidence of β-thalassaemia and sickle cell disease please provide the number of expected affected births/year (without prevention).
In Incidence of β-thalassaemia and sickle cell disease please provide the number of affected births/year (after prevention).

Haemoglobinopathy	Provide value		Comment
Prevalence of β-thalassaemia carriers		% of the population
Prevalence of sickle cell disease carriers		% of the population
Prevalence of α-thalassaemia carriers		% of the population
Prevalence of Hb E carriers		% of the population
Prevalence of Hb C carriers		% of the population
Expected incidence of β-thalassaemia		expected affected births/year
Expected incidence of sickle cell disease		expected affected births/year
Expected incidence of α-thalassaemia		expected affected births/year
Incidence of β-thalassaemia		affected births/year
Incidence of sickle cell disease		affected births/year
Incidence of α-thalassaemia		affected births/year
Known β-thalassaemia patients		patients
Known sickle cell disease patients		patients

Mutation Frequencies

Please provide details about publications reporting mutation frequencies in the country of reference (either country-wide studies or region-specific studies).

Show on map:		Information to display:
Minimum sample size: